Your browser doesn't support javascript.
loading
A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis.
Petrou, Panayiota; Kassis, Ibrahim; Yaghmour, Nour Eddine; Ginzberg, Ariel; Karussis, Dimitrios.
Afiliación
  • Petrou P; Unit of Neuroimmunology and Multiple Sclerosis Center and The Agnes-Ginges Center for Neurogenetics, Hadassah University Hospital, Ein-Kerem, 91120 Jerusalem, Israel.
  • Kassis I; Unit of Neuroimmunology and Multiple Sclerosis Center and The Agnes-Ginges Center for Neurogenetics, Hadassah University Hospital, Ein-Kerem, 91120 Jerusalem, Israel.
  • Yaghmour NE; Unit of Neuroimmunology and Multiple Sclerosis Center and The Agnes-Ginges Center for Neurogenetics, Hadassah University Hospital, Ein-Kerem, 91120 Jerusalem, Israel.
  • Ginzberg A; Unit of Neuroimmunology and Multiple Sclerosis Center and The Agnes-Ginges Center for Neurogenetics, Hadassah University Hospital, Ein-Kerem, 91120 Jerusalem, Israel.
  • Karussis D; Unit of Neuroimmunology and Multiple Sclerosis Center and The Agnes-Ginges Center for Neurogenetics, Hadassah University Hospital, Ein-Kerem, 91120 Jerusalem, Israel.
Front Biosci (Landmark Ed) ; 26(10): 693-706, 2021 10 30.
Article en En | MEDLINE | ID: mdl-34719198
ABSTRACT

Background:

Mesenchymal stem cells (MSC) were shown to induce beneficial effects in animal models of neurodegeneration and in pilot human trials in multiple sclerosis and amyotrophic lateral sclerosis (ALS).

Aim:

An open-label, clinical trial to evaluate the safety and efficacy of repeated intrathecal administrations of autologous-MSC in ALS-patients.

Methods:

The study included 20 subjects (age 20-70) with definite diagnosis of ALS and Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) score of >20. The patients were treated with 1-4 intrathecal injections of MSC, at intervals of 3-6 months. The primary endpoints were safety and tolerability. Efficacy measurements including ALSFRS-R score and forced vital capacity (FVC), were assessed as secondary endpoints.

Results:

No serious adverse events were observed during the whole period of the trial. One patient withdrew from the study before the first injection. The monthly rate of progression in ALSFRS-R was ameliorated by more than 25% in 15/19 patients between the 1st and 2nd injection (mean improvement of 107.1%); in 11/12 between the 2nd and 3rd injection and in 8/10 between the 3rd and 4th injection. Overall, during the whole period till the last transplantation 13 patients had a >25% improvement in the slope of progression of ALSFRS-R (mean improvement of 47.4%, p < 0.0038, Wilcoxon rank signed test). 7 out of 19 patients actually improved clinically (range of increase in ALSFRS-R +1 to +4 degrees) after the first transplantation and 5 remained improved after the second cycle. The response rate correlated with the time-intervals between the injections.

Conclusion:

The results of our study show that repeated intrathecal injections of autologous MSC was safe in patients with ALS and provide indications of medium-term clinical benefits that were related to the intervals between the administrations of the cells. Larger studies are needed to confirm these observations.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Trasplante de Células Madre Mesenquimatosas / Células Madre Mesenquimatosas / Esclerosis Amiotrófica Lateral Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Humans / Middle aged Idioma: En Revista: Front Biosci (Landmark Ed) Año: 2021 Tipo del documento: Article País de afiliación: Israel

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Trasplante de Células Madre Mesenquimatosas / Células Madre Mesenquimatosas / Esclerosis Amiotrófica Lateral Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Humans / Middle aged Idioma: En Revista: Front Biosci (Landmark Ed) Año: 2021 Tipo del documento: Article País de afiliación: Israel
...